Pfizer and German biotechnology company BioNTech announced on 9 November 2020 that an interim analysis of their COVID-19 vaccine trial indicated efficacy above 90 percent among participants without prior evidence of infection.

Promising trial signal

The companies said the analysis was conducted by an independent monitoring board during a large randomized phase-three trial. They cautioned that safety monitoring and additional data collection were still required before seeking emergency authorization.

European scientific contribution

BioNTech developed the messenger-RNA vaccine platform, while Pfizer supported global trials, manufacturing and distribution. The result validated a technology that had not previously produced a widely authorized human vaccine.

Global significance

The announcement offered the first strong evidence that vaccination could substantially reduce symptomatic COVID-19. It also created logistical challenges because early formulations required very cold storage and global demand greatly exceeded initial supply.

Sources

• Pfizer and BioNTech: interim analysis announcement
• European Medicines Agency: later authorization assessment

Featured image is illustrative. Photo by Spencer Davis on Unsplash.